Nevro Announced The Publication Of New Data Validating The Health Economic Benefits Of 10 Khz Therapy, Nevro's Proprietary High-frequency, 10 Khz Spinal Cord Stimulation Therapy
Portfolio Pulse from Benzinga Newsdesk
Nevro Corp. has announced the publication of new data validating the health economic benefits of its proprietary high-frequency, 10 kHz spinal cord stimulation therapy. The data supports the cost-effectiveness of the therapy.
September 18, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of new data validating the health economic benefits of Nevro's 10 kHz therapy could potentially boost the company's reputation and increase demand for its therapy.
The new data validates the cost-effectiveness of Nevro's 10 kHz therapy. This could potentially increase the demand for the therapy, leading to increased revenues for the company. The news is highly relevant as it directly pertains to Nevro's proprietary therapy and could have a significant impact on the company's financial performance.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100